16:17 , May 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample and mouse studies suggest inhibiting AEBP1 could help treat non-alcoholic steatohepatitis (NASH). In liver samples from NASH patients, hepatic stellate cell (HSC) levels of AEBP1 were higher than in...